The medical community at large has viewed with enthusiasm the success associated with immunotherapy through PD-1 blockade for mismatch repair deficient colorectal cancer. This is the initial study on patients with locally advanced rectal cancer, none of whom required salvage surgery. Subsequent studies ...
Head and neck cancer refers to malignancies originating mainly from the mucosal surfaces of the nose, mouth, and throat. Squamous cell carcinoma is by far the most common type of head and neck cancer, and immunotherapy is a core component of treatment for advanced and metastatic disease. Large...
Immunotherapy has become a valuable tool for the treatment of patients with various types of lymphomas because of its ability to specifically target cancer cells, particularly those in blood cancers, according to Stephen Ansell, MD, PhD. Compared with chemotherapy of the past, where treatment was ...
Betty Y. S. Kim is at the Departments of Neurosurgery, Cancer Biology and Neuroscience, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, Florida 32224, USA., Betty Y. S. Kim Charles K. Chan and Irving L. Weissman are at the Institute for Stem Cell Biology and Regenerative Medicine, Stanford...
On October 27, 2022, the 2nd Wuhan Forum of Immunotherapy for Pancreatic Cancer hosted by the Pancreatic Surgery Department of Union Hospital was successfully held online. The Forum invited a number of well-known experts and scholars in the field of immu
“Immunotherapy, in terms of biomarker-unselected populations, is probably the most promising [treatment] that we have identified in gastric/GEJ cancer,” said Harry H. Yoon, MD, co-chair, Esophageal/Gastric Cancer Disease Group, at Mayo Clinic. Pembrolizumab was approved for patients with PD-L1...
Pal, MD, on Renal Cancer Immunotherapy: Latest Developments Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging as...
Recent achievements in immunotherapy such as immne checkpoint inhibitors and chimeric antigen receptor T-cell therapy have revolutionized cancer treatments. By leveraging the patient’s own immune system, immunotherapy can now be applied in other disease contexts, including cardiac fibrosis and autoimmune ...
Experimental Hematology & Oncology (2024) 13:102 https://doi.org/10.1186/s40164-024-00570-y Experimental Hematology & Oncology REVIEW Open Access CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications Xiaohang Feng1, ...
W. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J. Leukoc. Biol. 64, 419–426 (1998). Article CAS PubMed Google Scholar Thiounn, N. et al. Adoptive immunotherapy for superficial bladder cancer with autologous macrophage ...